| Record ID | harvard_bibliographic_metadata/ab.bib.13.20150123.full.mrc:192030323:1469 |
| Source | harvard_bibliographic_metadata |
| Download Link | /show-records/harvard_bibliographic_metadata/ab.bib.13.20150123.full.mrc:192030323:1469?format=raw |
LEADER: 01469nam a2200373 a 4500
001 013162735-X
005 20120421023637.0
006 m d f
008 111213s2011 dcua ob f000 0 eng c
035 0 $aocn768191009
035 $a(FDLP)ocn768191009
040 $aGPO$cGPO
042 $apcc
043 $an-us---
074 $a0546-D (online)
086 0 $aGA 1.13:GAO-11-836
088 $aGAO-11-836
110 1 $aUnited States.$bGovernment Accountability Office.
245 10 $aDrug pricing$h[electronic resource] :$bmanufacturer discounts in the 340B program offer benefits, but federal oversight needs improvement : report to congressional committees.
246 30 $aManufacturer discounts in the 340B program offer benefits, but federal oversight needs improvement
246 17 $aDrug Pricing Program
260 $a[Washington, D.C.] :$bU.S. Govt. Accountability Office,$c[2011]
300 $a1 online resource (ii, 49 p.) :$bill.
500 $aTitle from PDF title screen (viewed Dec. 8, 2011).
500 $a"September 2011."
504 $aIncludes bibliographical references.
500 $a"GAO-11-836."
650 0 $aDrugs$xPrices$zUnited States.
650 0 $aPrescription pricing$zUnited States.
650 0 $aPharmaceutical industry$zUnited States.
650 0 $aConsumer protection$zUnited States.
610 10 $aUnited States.$bHealth Resources and Services Administration$xRules and practice.
988 $a20120421
906 $0OCLC